CPC-100, Colby’s lead drug will be entering the clinic in 2008 for men who have already been treated with surgery or radiation for their primary prostate tumor and have subsequently failed Androgen Depletion Therapy (ADT, the current standard of care), as indicated by their rising serum PSA levels. These men are often are without radiographic evidence of tumor metastatsis to bone or soft tissue. CPC-100 is an anti-Androgenic anti-Inflammatory Oxidative Stress Modulator drug and is different from all the Androgen Receptor-binding anti-Androgenic drugs currently in the market, which are only effective for the treatment of Androgen-dependent prostate tumors. In contrast, CPC-100 is therapeutic for the treatment of both Androgen-dependent or Androgen-independent prostate cancers. CPC-100 is also unlike other anti-Androgens, as it does not have pro-Estrogenic negative side effects.
CPC-100 Mechanism of Aciton
